Ana García Martínez-rekin lankidetzan egindako argitalpenak (14)

2013

  1. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 9, pp. 1481-1487

2012

  1. Cytokines and Vascular Inflammation

    Inflammatory Diseases of Blood Vessels: Second Edition (Wiley-Blackwell), pp. 82-93

2011

  1. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.

    Rheumatology (Oxford, England), Vol. 50, Núm. 11, pp. 2061-2070

2010

  1. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin-6) in the long-term followup of patients with giant cell arteritis

    Arthritis Care and Research, Vol. 62, Núm. 6, pp. 835-841

  2. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: Association between elevated plasma endothelin levels and the development of ischaemic events

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 2, pp. 434-442

2009

  1. The spectrum of vascular involvement in giant-cell arteritis: Clinical consequences of detrimental vascular remodelling at different sites

    APMIS

2008

  1. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients

    Arthritis Care and Research, Vol. 59, Núm. 3, pp. 422-430

  2. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 11, pp. 1581-1588

  3. New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents

    Clinical and Experimental Rheumatology, Vol. 26, Núm. 3 SUPPL. 49

2007

  1. Gelatinase expression and proteolytic activity in giant-cell arteritis

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 11, pp. 1429-1435

2006

  1. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis

    Rheumatology, Vol. 45, Núm. 11, pp. 1356-1363

2004

  1. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

    Current rheumatology reports, Vol. 6, Núm. 3, pp. 184-194

  2. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intesity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis

    Rheumatology, Vol. 43, Núm. 3, pp. 294-301

2003

  1. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism

    Circulation, Vol. 107, Núm. 19, pp. 2428-2434